VBI VACCINES INC (VBIV)

CA91822J2020 - Common Stock

0.63  -0.02 (-3.02%)

After market: 0.625 -0.01 (-0.79%)

News Image
4 days ago - InvestorPlace

VBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024

VBIV stock results show that VBI Vaccines missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

News Image
4 days ago - BusinessInsider

VBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips VBI Vaccines (NASDAQ:VBIV) just reported results for the first quarter of 2024....

News Image
a month ago - InvestorPlace

VBIV Stock Earnings: VBI Vaccines Beats EPS, Misses Revenue for Q4 2023

VBIV stock results show that VBI Vaccines beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.

News Image
a month ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to dive into all of the biggest pre-market stock movers that traders will want to keep an eye on Friday morning!

News Image
2 months ago - Brii Biosciences Limited

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational...

News Image
3 months ago - Seeking Alpha

VBI signs deal to sell manufacturing capabilities, certain assets with Brii Biosciences

Biopharmaceutical firm VBI Vaccines rose over 7% in premarket trading as Brii Biosciences announced the acquisition of VBI's HBV immunotherapeutic...

News Image
3 months ago - Brii Biosciences Limited

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and royalty payments to VBI, subject to achievement of certain...

News Image
9 months ago - Seeking Alpha

VBI Vaccines stock gains after data for Hep B candidate

Read why VBI Vaccines (VBIV) traded higher Wednesday after its partner Brii Biosciences Limited (BRIBF), announced mid-stage data for Hep B drug BRII-179.

News Image
9 months ago - Brii Biosciences Limited

Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve...

News Image
10 months ago - InvestorPlace

7 Biotech Stocks to Sell in July

Running the gamut from large to small, and from commercial stage to clinical stage, these are seven top biotech stocks to sell in July.